Cantor Fitzgerald Calls Candel Therapeutics Deeply Undervalued – Overweight Rating Initiated
Cantor is very bullish on CADL, sees big undervaluation and CAN-2409 as a major drug with huge growth potential.
/ 2 items
Cantor is very bullish on CADL, sees big undervaluation and CAN-2409 as a major drug with huge growth potential.
Candel earned a $15 stock rating. Its key drug, CAN-2409, is seen as transformative because it improves current treatments.